Theravance Biopharma's New Research on Ampreloxetine at AAN 2025 Highlights Drug's Potential for Neurogenic Orthostatic Hypotension Theravance Biopharma showcased new findings on ampreloxetine in the context of neurogenic orthostatic hypotension at AAN 2025, highlighting its promising efficacy and safety.

Theravance Biopharma's New Research on Ampreloxetine at AAN 2025 Highlights Drug's Potential for Neurogenic Orthostatic Hypotension #Ireland #Dublin #Theravance_Biopharma #Ampreloxetine #Neurogenic_Orthostatic